Shikha Gupta, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Excited to have shared our research on CDK4/6 inhibitors as a promising therapeutic approach in translocation renal cell carcinoma at ENA Symp 24.
We’re hopeful that our findings will pave the way for future clinical trials & provide new treatment avenues for tRCC patients.”
